Incyte (INCY) Saham Harga
Incyte Harga
Selama 19 tahun terakhir pendapatan Incyte tumbuh 31,7% per tahun, mencapai 5,14 miliar USD. Laba per saham tumbuh 68,6% per tahun selama 10 tahun terakhir. Bagi Incyte, margin bersih sebesar 25,0% turun dibanding 31,8% beberapa tahun lalu. Target harga konsensus 12 bulan untuk Incyte adalah 130,00 USD, sekitar di atas harga saat ini 15,4%. Dari 35 analis, 18 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Incyte
Model bisnis dan analisis saham Incyte
Pertanyaan yang sering diajukan tentang saham Incyte
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Analis saat ini menetapkan target harga rata-rata 128,38 USD untuk saham Incyte (median: 130,00 USD), yaitu +14,0 % terhadap harga terbaru. Konsensus didasarkan pada 35 peringkat analis.
35 analis saat ini menilai saham Incyte: 18 merekomendasikan beli, 17 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Incyte menghasilkan pendapatan 5,94 miliar USD dan laba per saham 3,41 USD.
Dengan kurs saat ini, saham Incyte diperdagangkan pada 100,50 EUR (112,61 USD).
Saham Incyte (INCY) tercatat di 8 bursa, termasuk: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
Pendapatan diperkirakan dari Incyte adalah 5,94 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Incyte adalah 697,46 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Incyte saat ini adalah 33,06. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Incyte.
Rasio harga-terhadap-penjualan (PSR) Incyte saat ini adalah 3,88. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Incyte.
Skor Kualitas AlleAktien untuk Incyte adalah 6/10.
ISIN dari Incyte adalah US45337C1027. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Incyte adalah 896133. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Incyte adalah INCY. Simbol ticker digunakan untuk memperdagangkan saham Incyte di bursa saham.
Saham Incyte
Kelompok Peer Incyte
Incyte Ticker
Incyte FIGI
Semua metrik fundamental dan analisis mendalam Incyte
Analisis saham kami untuk saham Incyte mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Incyte. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.